General discussion, page-2682

Understanding the inflammation cascade that is in play here now and the end organ morbidity associated with it for sufferers of OSAS.....
(not to mention the major pathological factor associated with CVD, diabetes mellitus, and nervous system diseases such as dementia, Parkinson’s disease, Alzheimer’s disease, and epilepsy )

then with fresh eyes on the release of 'Incannex partnering with the Alfred' and Professor Obrien 'coming into the tent' so to speak - as the Principal investigator -



'Incannex will endeavour to supply IHL-42X for sale in Australia under the Special Access Scheme for unregistered medicinal cannabis products, alongside its existing range of cannabinoid oils and CBD Inhaler.'

'IHL will also proceed to the second Phase 2 ‘Factorial’ clinical trial as it compiles the necessary information for an FDA 505(b)(2) new drug application for exclusive marketability; details of which were released in the announcement on the 25th of March 2020 and entitled, “IHL-42X (OSA) accelerated FDA approval pathway”.'

Incannex has filed patents over the use of IHL-42X drug to be delivered to patient as a nocturnally administered pill to treat OSA.

Should IHL 42X return positive results from the clinical trials then potentially another unmet need finds a treatment - seems so ridiculous in the face of all the recorded research data the only solution was a was combination of ineffective pharmaceuticals( with side effects) and a
CPAP( simplified explanation but no less a relevant statement - suspecting it may well add to the localised and acute levels of inflammation -
this is my own opinion )
A once nightly oral pharmaceutical has to be better than this ( should it prove efficacious)

looking forward to the news flow - potentially huge - all in my own opinion
may need another parcel next week before the SP climbs further

not intended as financial advice